Mohammed Shatat, MD | American Lung Association

Mohammed Shatat, MD

Research Awards Nationwide Recipient (2014-2016)

Case Western Reserve University, Cleveland, OH
Molecule Could Play Role in Improving Treatment of PAH

Pulmonary arterial hypertension (PAH) is a serious disease characterized by elevated pressure in the vessels that carry blood from the heart to the lungs. This causes the right side of the lung to become strained and, over time, can lead to heart failure. We have found that KLF4, a molecule present in the endothelial cells lining the blood vessels has a protective effect against the development of PAH. We will study the role of KLF4 in regulating endothelial progenitor cells (EPCs), which participate in repairing damaged endothelial cells and are being studied for treating PAH. Understanding the role of KLF4 in regulating EPC function may help enhance their use in therapy.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.